FDA finds gepirone ER “not approvable” as a treatment for Major Depressive Disorder

The U.S. Food and Drug Administration has determined that Organon’s gepirone ER New Drug Application is “not approvable.”

This action is the FDA’s response to an amendment to Organon’s New Drug Application submitted to the FDA in December 2003. Organon plans to withdraw the application for gepirone as a treatment for major depressive disorder.

“Organon is disappointed in this response from the FDA and we are moving forward with our next steps in the development of products for mental health” said Toon Wilderbeek, Organon International President and Akzo Nobel Board Member.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Largest study using machine learning in neuroimaging sets new benchmark for major depression diagnosis